ANAPTYSBIO, INC
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $234.6M | $91.3M | $17.2M | $10.3M | $63.2M |
| Operating income | $47.9M | -$114.9M | -$164.4M | -$115.2M | -$56.8M |
| Operating expenses | $186.7M | $206.2M | $181.6M | $125.4M | $120.0M |
| Cash from operations | $19.7M | -$135.3M | -$120.8M | -$73.6M | -$45.9M |
| Capital expenditure | $87,000 | $358,000 | $807,000 | $358,000 | $1.4M |
| Free cash flow | $19.6M | -$135.7M | -$121.6M | -$74.0M | -$47.3M |
| Share repurchases | $68.6M | $456,000 | $50.0M | $0 | $0 |
| Impairments | $0 | $0 | $0 | $0 | $0 |
| Total assets | $364.4M | $483.8M | $452.4M | $610.4M | $643.1M |
Shares outstanding 29.1M · Free float 17.5%
Annual filing data through FY ended December 31, 2025; float as of July 13, 2026.